MCID: OVR049
MIFTS: 59

Ovarian Disease

Categories: Endocrine diseases, Reproductive diseases, Rare diseases, Genetic diseases

Aliases & Classifications for Ovarian Disease

MalaCards integrated aliases for Ovarian Disease:

Name: Ovarian Disease 12 15
Ovarian Dysfunction 12 55 15
Ovarian Diseases 55 44 73
Disorder of Endocrine Ovary 73
Ovarian Disorders 43

Classifications:



External Ids:

Disease Ontology 12 DOID:1100 DOID:1414
MeSH 44 D010049
NCIt 50 C26841
ICD9CM 35 256.3 256.39
ICD10 33 E28 E28.3 E28.9

Summaries for Ovarian Disease

MedlinePlus : 43 The ovaries are part of the female reproductive system. Women have two ovaries, one on each side of the uterus. Each ovary is about the size and shape of an almond. The ovaries produce and store a woman's eggs. During ovulation, an ovary releases an egg. If that egg is fertilized by a sperm, a pregnancy can occur. Ovaries also make the female hormones estrogen and progesterone. When a woman goes through menopause, her ovaries stop making those hormones and releasing eggs. Problems with the ovaries include Ovarian cancer Ovarian cysts and polycystic ovary syndrome Primary ovarian insufficiency Ovarian torsion, a twisting of the ovary

MalaCards based summary : Ovarian Disease, also known as ovarian dysfunction, is related to hyperprolactinemia and hyperinsulinism, and has symptoms including pelvic pain and mittelschmerz. An important gene associated with Ovarian Disease is GNRH1 (Gonadotropin Releasing Hormone 1), and among its related pathways/superpathways are Glucose / Energy Metabolism and Prolactin Signaling Pathway. The drugs Metformin and Letrozole have been mentioned in the context of this disorder. Affiliated tissues include ovary, testes and t cells, and related phenotypes are endocrine/exocrine gland and homeostasis/metabolism

Wikipedia : 76 Ovarian diseases can be classified as endocrine disorders or as a disorders of the reproductive... more...

Related Diseases for Ovarian Disease

Diseases in the Ovarian Disease family:

Ovarian Insufficiency, Familial Fmr1-Related Primary Ovarian Insufficiency
Ovarian Insufficiency Due to Fsh Resistance

Diseases related to Ovarian Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 109)
# Related Disease Score Top Affiliating Genes
1 hyperprolactinemia 30.5 GNRH1 IGF1 PRL SHBG
2 hyperinsulinism 30.4 IGF1 IGFBP1 INS SHBG
3 hypogonadotropism 30.3 GNRH1 PRL
4 insulin-like growth factor i 30.2 IGF1 IGFBP1 INS PRL SHBG
5 luteoma 30.1 CGA CYP19A1
6 acanthosis nigricans 30.1 IGF1 INS PRL SHBG
7 pituitary gland disease 30.0 GNRH1 IGF1 INS PRL
8 anorexia nervosa 29.6 IGF1 IGFBP1 PRL
9 hyperandrogenism 29.5 CYP19A1 GNRH1 IGF1 IGFBP1 INS PRL
10 endometrial cancer 29.2 CYP19A1 GNRH1 IGF1 IGFBP1 INS SHBG
11 ovarian hyperstimulation syndrome 29.2 AMH CGA CYP19A1 FSHR GNRH1
12 polycystic ovary syndrome 29.2 CYP11A1 CYP19A1 FSHR GDF9 GNRH1 IGF1
13 amenorrhea 29.1 BMP15 FSHR GNRH1 NOBOX PRL SHBG
14 infertility 29.0 CYP19A1 FSHR GNRH1 PRL ZP1 ZP3
15 anovulation 27.9 BMP15 CGA CYP19A1 FSHR GNRH1 IGF1
16 premature ovarian failure 1 25.8 AMH BMP15 CYP11A1 CYP19A1 FMR1 FOXL2
17 mullerian aplasia and hyperandrogenism 11.1
18 secondary adrenal insufficiency 10.9 IGF1 INS
19 galactorrhea 10.9 IGF1 PRL
20 pineal hyperplasia, insulin-resistant diabetes mellitus, and somatic abnormalities 10.9 IGF1 INS
21 hypoactive sexual desire disorder 10.9 CYP19A1 SHBG
22 leukoencephalopathy with vanishing white matter 10.8
23 endometriosis of uterus 10.8 GNRH1 PRL
24 hyperproinsulinemia 10.8 IGFBP1 INS SHBG
25 sheehan syndrome 10.8 IGF1 INS PRL
26 pituitary apoplexy 10.8 GNRH1 INS PRL
27 precocious puberty, male-limited 10.8 CYP19A1 FSHR
28 pseudohypoparathyroidism, type ia 10.8 IGF1 PRL
29 hyperpituitarism 10.8 IGF1 INS PRL
30 pituitary infarct 10.8 GNRH1 IGF1 PRL
31 androgen insensitivity, partial 10.8 CYP19A1 SHBG
32 empty sella syndrome 10.8 GNRH1 IGF1 PRL
33 hypogonadotropic hypogonadism 23 without anosmia 10.7 FSHR GNRH1
34 thyroid gland disease 10.7 IGF1 INS PRL
35 androgenic alopecia 10.7 CYP19A1 PRL SHBG
36 hypothalamic disease 10.7 GNRH1 PRL
37 mammographic density 10.7 CYP19A1 IGF1 PRL
38 cell type benign neoplasm 10.7 IGF1 INS PRL
39 chromophobe adenoma 10.7 GNRH1 INS PRL
40 premenstrual tension 10.7 GNRH1 PRL SHBG
41 pituitary-dependent cushing's disease 10.7 GNRH1 INS PRL
42 aromatase deficiency 10.7 CYP19A1 GNRH1 INS
43 turner syndrome 10.7 IGF1 IGFBP1 SHBG
44 overnutrition 10.7 IGF1 INS SHBG
45 chiasmal syndrome 10.7 GNRH1 PRL
46 estrogen excess 10.7 CYP19A1 FSHR SHBG
47 male reproductive organ cancer 10.7 GNRH1 IGF1 SHBG
48 complete androgen insensitivity syndrome 10.7 CGA CYP19A1 SHBG
49 breast disease 10.7 IGF1 PRL SHBG
50 granulosa cell tumor of the ovary 10.7 FOXL2 INS PRL

Graphical network of the top 20 diseases related to Ovarian Disease:



Diseases related to Ovarian Disease

Symptoms & Phenotypes for Ovarian Disease

UMLS symptoms related to Ovarian Disease:


pelvic pain, mittelschmerz

MGI Mouse Phenotypes related to Ovarian Disease:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 endocrine/exocrine gland MP:0005379 10.16 IGF1 CYP11A1 INS CYP19A1 NOBOX FMR1
2 homeostasis/metabolism MP:0005376 9.93 CGA IGF1 CYP11A1 INS CYP19A1 PRL
3 nervous system MP:0003631 9.65 CGA IGF1 CYP11A1 INS CYP19A1 NOBOX
4 reproductive system MP:0005389 9.53 IGF1 CYP11A1 INS CYP19A1 NOBOX FMR1

Drugs & Therapeutics for Ovarian Disease

Drugs for Ovarian Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 684)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Metformin Approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1 657-24-9 14219 4091
2
Letrozole Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 112809-51-5 3902
3
Cyproterone Acetate Approved, Investigational Phase 4,Phase 2,Phase 3,Early Phase 1,Not Applicable 427-51-0
4
Drospirenone Approved Phase 4,Phase 3,Phase 1,Not Applicable 67392-87-4 68873
5
Estradiol Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 50-28-2 5757
6 Estradiol valerate Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 979-32-8
7
Ethinyl Estradiol Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 57-63-6 5991
8
Polyestradiol phosphate Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 28014-46-2
9
Orlistat Approved, Investigational Phase 4,Phase 2,Not Applicable 96829-58-2 3034010
10
Ganirelix Approved Phase 4,Phase 2,Not Applicable,Early Phase 1 123246-29-7, 124904-93-4 25081094
11
Progesterone Approved, Vet_approved Phase 4,Phase 3,Phase 1,Not Applicable,Early Phase 1 57-83-0 5994
12
Leuprolide Approved, Investigational Phase 4,Phase 2,Not Applicable,Early Phase 1 53714-56-0 3911 657181
13
Menotropins Approved Phase 4,Phase 2,Phase 1,Not Applicable 61489-71-2, 9002-68-0 5360545
14
Pioglitazone Approved, Investigational Phase 4,Not Applicable,Early Phase 1 111025-46-8 4829
15
Dexamethasone Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 50-02-2 5743
16
Doxorubicin Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 23214-92-8 31703
17
Simvastatin Approved Phase 4,Phase 3,Not Applicable 79902-63-9 54454
18
Zinc Approved, Investigational Phase 4,Early Phase 1,Not Applicable 7440-66-6 23994
19
Hydrocortisone Approved, Vet_approved Phase 4,Not Applicable,Early Phase 1 50-23-7 5754
20
Resveratrol Approved, Experimental, Investigational Phase 4,Phase 1,Not Applicable 501-36-0 445154
21
Lenograstim Approved, Investigational Phase 4,Phase 3,Phase 1,Phase 2 135968-09-1
22
Bevacizumab Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable 216974-75-3
23
Carboplatin Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 41575-94-4 10339178 498142 38904
24
Paclitaxel Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 33069-62-4 36314
25
Testosterone Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 58-22-0 6013
26
Medroxyprogesterone acetate Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 71-58-9
27
Olaparib Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable 763113-22-0 23725625
28
Buserelin Approved, Investigational Phase 4 57982-77-1
29
Nafarelin Approved Phase 4 76932-56-4 16129618 25077649
30
Aspirin Approved, Vet_approved Phase 4,Phase 2,Early Phase 1 50-78-2 2244
31
Liraglutide Approved Phase 4 204656-20-2 44147092
32
Alogliptin Approved Phase 4 850649-61-5 11450633
33
Danazol Approved Phase 4 17230-88-5 28417
34
Acetylcysteine Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 616-91-1 12035
35
Citalopram Approved Phase 4 59729-33-8 2771
36
Epinephrine Approved, Vet_approved Phase 4,Phase 2,Phase 3,Not Applicable,Early Phase 1 51-43-4 5816
37
Racepinephrine Approved Phase 4,Phase 2,Phase 3,Not Applicable,Early Phase 1 329-65-7 838
38
Tranexamic Acid Approved Phase 4 1197-18-8 5526
39
Norethindrone Approved Phase 4,Phase 2,Not Applicable,Early Phase 1 68-22-4 6230
40
Moxonidine Approved, Investigational Phase 4 75438-57-2 4810
41
Hydroxocobalamin Approved Phase 4,Not Applicable 13422-51-0 11953898 44475014
42
Acarbose Approved, Investigational Phase 4,Not Applicable 56180-94-0 441184
43
Rosiglitazone Approved, Investigational Phase 4,Not Applicable 122320-73-4 77999
44
Etoricoxib Approved, Investigational Phase 4 202409-33-4 123619
45
Hyaluronic acid Approved, Vet_approved Phase 4,Not Applicable 9004-61-9 53477741
46
Exenatide Approved, Investigational Phase 4,Phase 3,Phase 2 141758-74-9 15991534
47
Desogestrel Approved Phase 4,Phase 3,Phase 2 54024-22-5 40973
48
Methylprednisolone Approved, Vet_approved Phase 4,Phase 1,Phase 2 83-43-2 6741
49
Prednisolone Approved, Vet_approved Phase 4,Phase 1,Phase 2 50-24-8 5755
50
Iron Approved Phase 4,Phase 2,Not Applicable 7439-89-6 23925

Interventional clinical trials:

(show top 50) (show all 2299)
# Name Status NCT ID Phase Drugs
1 Metformin for the Treatment of Unexplained Oligozspermia Unknown status NCT01529177 Phase 4 Metformin / clomid / hCG;Clomiphene citrate / hCG
2 Administration of Single High Dose Letrozole for Ovulation Induction Unknown status NCT02703649 Phase 4 Letrozole
3 The Impact on Ovarian Reserve After Single-port, Two-port, or Four-port Access Laparoscopic Ovarian Cyst Enucleation Unknown status NCT01631253 Phase 4
4 Hemocoagulation and Lipoperoxidation in Women Using Combined Oral Contraceptives, Correction by Antioxidants Unknown status NCT02027337 Phase 4 20 mcg ethinylestradiol /3 mg drospirenone;20 mcg ethinylestradiol/3 mg drospirenone and Selmevit;30 mcg ethinylestradiol/3 mg drospirenone;30 mcg ethinylestradiol/3 mg drospirenone and Selmevit;35 mcg ethinylestradiol/2 mg cyproterone;35 mcg ethinylestradiol/2 mg cyproterone and Selmevit
5 Effects of ADSC Therapy in Women With POF Unknown status NCT01853501 Phase 4
6 Myoinositol for the Treatment of Ovarian and Psychiatric Disorder in Polycystic Ovary Syndrome (PCOS) Patients Unknown status NCT01246310 Phase 4
7 Endometrial Scratching During Laproscopic Ovarian Drilling in Subfertile PCOS Women Unknown status NCT02140398 Phase 4
8 the Effect of Diane-35 Pretreatment on In-vitro Fertilization Outcome for Patients With Polycystic Ovary Syndrome Unknown status NCT01752270 Phase 4 Diane-35 pretreatment;Diane-35 pretreatment
9 Metformin in Infertile PCOS Patients Unknown status NCT00501904 Phase 4 Metformin
10 Therapeutic Monitoring of Metformin in Women With Polycystic Ovary Syndrome Unknown status NCT01366391 Phase 4 Metformin
11 The Effect of Weight Loss on Anti-Müllerian Hormone Levels in Women With Polycystic Ovary Syndrome (PCOS) Unknown status NCT01475019 Phase 4 Orlistat;Sibutramine
12 Metformin and Gestational Diabetes in High-risk Patients: a RCTs Unknown status NCT00883259 Phase 4 Metformin
13 Comparison Between GnRH Agonist and GnRH Antagonist Protocols of Ovarian Stimulation in PCOS Patients Unknown status NCT00417144 Phase 4 Arvekap 0.1mg (Triptorelin, Ipsen, France);Ganirelix 0.25mg (Orgalutran, Organon, The Netherlands)
14 Surgical Ovarian Drilling Versus Hormonal Treatment for Infertility Associated to PolyCystic Ovaries Syndrome (PCOS) Unknown status NCT00378729 Phase 4 Metformin and FSHr
15 Strategies for Ovulation Induction in Anovulatory Infertile Patients With PCOS Unknown status NCT00461643 Phase 4 Clomiphene citrate, metformin, metformin plus clomiphene citrate, gonadotropins
16 Co-administration of Low Dose hCG at the Time of GnRH Agonist Trigger or 35 Hours Later for the Prevention of OHSS Completed NCT01815138 Phase 4 hCG;hCG
17 Endometrial Receptivity After GnRH Agonist Triggering Completed NCT01500863 Phase 4 hCG;triptorelin;Triptorelin, estradiol valerate, micronized vaginal progesterone;triptorelin, hCG;triptorelin, hCG;triptorelin, recombinant LH
18 Triggering of Final Oocyte Maturation With GnRHa (Buserelin) in GnRH Antagonist Cycles Completed NCT00627406 Phase 4 Buserelin and Pregnyl;Pregnyl;Buserelin and Pregnyl;Pregnyl
19 The Use of GnRH Agonist Trigger in the Prevention of OHSS Completed NCT00349258 Phase 4 Leuprolide acetate
20 FSH in GnRH-AntagoniST Controlled Ovarian Hyperstimulation Cycles (FAST) Completed NCT01969201 Phase 4 Urofollitrophin;Follitrophin alpha
21 Gonadotrophin Dosage Using a Threshold Nomogram for Ovulation Induction in WHO Group II Anovulatory Infertility Completed NCT01250821 Phase 4 Menopur
22 Short Versus Long Protocol for IVF and IVF+ICSI Completed NCT00756028 Phase 4 Patients receiving short protocol IVF/ICSI-treatment.;Long protocol
23 Flexible GnRH Antagonist vs Flare up GnRH Agonist Protocol in Poor Responders Completed NCT00417066 Phase 4 Ganirelix 0.25mg (Orgalutran, Organon, The Netherlands);Arvekap 0.1mg (Triptorelin, Ipsen, France)
24 Preventive Application of Letrozole Decrease Incidence of Early Onset of OHSS Completed NCT02670304 Phase 4 letrozole;Aspirin
25 The Role of Estrogen in Luteinizing Hormone Surge and Ovulation Completed NCT01999569 Phase 4 Letrozole
26 Sitagliptin Improved Beta Cell Function and Prevented a Conversion Rate to Impaired Glucose Tolerance and Type 2 Diabetes in Metformin Intolerant Obese Women With Polycystic Ovary Syndrome Completed NCT03122041 Phase 4 Sitagliptin
27 Weight Maintenance With Dipeptidyl Peptidase 4 (DPP4) Inhibitor Sitagliptin in Combination With Metformin After Liragludite Induced Weight Loss Completed NCT02941445 Phase 4 sitagliptin and metformin;Metformin
28 The Effect of Metformin on Different Hormones in PCOS Patients Completed NCT02568488 Phase 4 Metformin
29 Liraglutide as Add on Therapy on Metformin in Women With Polycystic Ovary Syndrome Completed NCT02483299 Phase 4 Metformin;Glucophage tablets and Victoza
30 Phytoestrogens as an Alternative to Estradiol in Ovulation Induction in PCOS Completed NCT02352597 Phase 4 phytoestrogen;estradiol valerate;clomiphene citrate
31 PDE-4 Inhibitor Roflumilast and GLP-1 Agonist Liraglutide in Polycystic Ovary Syndrome Completed NCT02187250 Phase 4 metformin;liraglutide;roflumilast
32 PDE-4 Inhibitor Roflumilast and Polycystic Ovary Syndrome Completed NCT02037672 Phase 4 metformin;metformin and roflumilast
33 Clinical Evaluation of Furocyst in Patients With Poly Cystic Ovary Syndrome Completed NCT02789488 Phase 4
34 Polycystic Ovary Syndrome and Liraglutide as Add-on Therapy on Metformin Completed NCT01911468 Phase 4 metformin;liraglutide;metformin and liraglutide
35 Polycystic Ovary Syndrome and Liraglutide Completed NCT01899430 Phase 4 liraglutide;metformin
36 The Effect of a Liraglutide on IVF in Obese PCOS Completed NCT03353948 Phase 4 MET;COMBI
37 Vitamin D Treatment, Pharmacogenetics and Glucose Metabolism Completed NCT01721915 Phase 4 Vitamin D supplementation;Placebo
38 Medical Nutrition Therapy Plus Transgestational Metformin For Preventing Gestational Diabetes In High Risk Mexican Women Completed NCT01675310 Phase 4 medical nutrition therapy + metformin
39 The Use of 18F-ALF-NOTA-PRGD2 PET/CT Scan to Predict the Efficacy and Adverse Events of Apatinib in Malignancies. Completed NCT03384511 Phase 4 Apatinib
40 A Random Clinical Trial (RCT) of the Impact of Electrocoagulation on Ovarian Reserve Completed NCT00746278 Phase 4
41 The Effects of OCP and Metformin on Clinical, Hormonal, Metabolic and Ultrasonographic Characteristics in PCOS Completed NCT02866786 Phase 4 Metformin;ethinyl estradiol and cyproterone acetate
42 The Impact of Electrocoagulation on Ovarian Reserve After Laparoscopic Excision of Ovarian Cyst Completed NCT00713778 Phase 4
43 hMG or Recombinant FSH on OHSS Prevention in PCOS Patients Undergoing IVF Completed NCT01365936 Phase 4 HMG;rFSH
44 Low Dose Liraglutide and Metformin vs. High Dose Liraglutide Alone in Treatment of Obesity Completed NCT02909933 Phase 4 liraglutide;metformin and liraglutide
45 The Effects of Vitamin D on Transforming Growth Factor-beta1 in Polycystic Ovary Syndrome Completed NCT02460380 Phase 4 Vitamin D3
46 Comparison of Alogliptin Versus Alogliptin and Pioglitazone on Insulin Resistance of Metformin Treated Women With PCOS Completed NCT02683226 Phase 4 Vipdomet;Incresync
47 Danazol Treatment in Endometriosis Women Before IVF Completed NCT01779232 Phase 4 Danazol;placebo
48 Trial With Metformin in Women With Polycystic Ovary Syndrome Completed NCT02280057 Phase 4 Metformin;Placebo
49 Protexa® Versus TiLoopBra® in Immediate Breast Reconstruction- A Pilot Study Completed NCT02562170 Phase 4
50 N-acetyl Cysteine for Ovulation Induction in Clomiphene Citrate Resistant Polycystic Ovary Syndrome Completed NCT02239107 Phase 4 N-Acetyl cysteine

Search NIH Clinical Center for Ovarian Disease

Cochrane evidence based reviews: ovarian diseases

Genetic Tests for Ovarian Disease

Anatomical Context for Ovarian Disease

MalaCards organs/tissues related to Ovarian Disease:

41
Ovary, Testes, T Cells, Lung, Bone, Liver, Breast

Publications for Ovarian Disease

Articles related to Ovarian Disease:

(show top 50) (show all 454)
# Title Authors Year
1
Combined Cabergoline and Metformin in Patients with Polycystic Ovarian Disease with Hyperprolactinemia: Methodological Concerns. ( 29896007 )
2018
2
Reproductive performance in dairy cows with cystic ovarian disease after single treatment with buserelin acetate or dinoprost. ( 29848852 )
2018
3
Tumor necrosis factor alpha versus LH and androstendione as a reliable predictor of spontaneous ovulation after laparoscopic ovarian drilling for women with clomiphene citrate resistance polycystic ovarian disease. ( 29408743 )
2018
4
A Cross-sectional Study on the Proportion of Anxiety and Depression and Determinants of Quality of Life in Polycystic Ovarian Disease. ( 29875533 )
2018
5
Polycystic Ovarian Disease (Stein-Leventhal Syndrome) ( 29083730 )
2017
6
Efficacy of Combined Cabergoline and Metformin Compared to Metformin Alone on Cycle Regularity in Patients with Polycystic Ovarian Disease with Hyperprolactinemia: A Randomized Clinical Trial. ( 28867888 )
2017
7
Effects of liraglutide on ovarian dysfunction in polycystic ovary syndrome: a randomized clinical trial. ( 28479118 )
2017
8
Thyroid function/antibodies in sudanese women with polycystic ovarian disease. ( 28344960 )
2017
9
The role of regulatory T cells in thymectomy-induced autoimmune ovarian disease. ( 28660639 )
2017
10
Natural history of autoimmune primary ovarian insufficiency in patients with Addison's disease: from normal ovarian function to overt ovarian dysfunction. ( 28733292 )
2017
11
Polycystic ovarian disease and associated factors. ( 27075885 )
2016
12
Adiponectin Deficiency Leads to Female Subfertility and Ovarian Dysfunctions in Mice. ( 27700136 )
2016
13
A novel method of extraction of bamboo seed oil (Bambusa bambos Druce) and its promising effect on metabolic symptoms of experimentally induced polycystic ovarian disease. ( 27127318 )
2016
14
Molecular signatures of ovarian diseases: Insights from network medicine perspective. ( 27341345 )
2016
15
BMP2, 4 and 6 and BMPR1B are altered from early stages of bovine cystic ovarian disease development. ( 27486268 )
2016
16
Bidirectional Estrogen-Like Effects of Genistein on Murine Experimental Autoimmune Ovarian Disease. ( 27834809 )
2016
17
Involvement of Matrix Metalloproteinases and their Inhibitors in Bovine Cystic Ovarian Disease. ( 27993358 )
2016
18
Efficacy and toxicity of bevacizumab in recurrent ovarian disease: an update meta-analysis on phase III trials. ( 26657509 )
2016
19
Role of Glucocorticoids in Cystic Ovarian Disease: Expression of Glucocorticoid Receptor in the Bovine Ovary. ( 26677854 )
2016
20
Oral contraceptive pills induced hemichorea in an adolescent female with polycystic ovarian disease. ( 25878392 )
2015
21
Involvement of PAPP-A and IGFR1 in Cystic Ovarian Disease in Cattle. ( 26031184 )
2015
22
Molecular aspects of bovine cystic ovarian disease pathogenesis. ( 25767139 )
2015
23
Altered Expression of Pro-inflammatory Cytokines in Ovarian Follicles of Cows with Cystic Ovarian Disease. ( 26065705 )
2015
24
"Empiric" inositol supplementation in normal-weight non insulin resistant women with polycystic ovarian disease: from the absence of benefit to the potential adverse effects. ( 25687659 )
2015
25
Anti-mA1llerian hormone and insulin-like 3 levels in healthy normal-weight ovulatory and anovulatory eumenorrheic late adolescent females: potential early biomarkers of ovarian dysfunction? ( 26579638 )
2015
26
Authors' reply to: "Empiric" inositol supplementation in normal-weight non-insulin resistant women with polycystic ovarian disease: from the absence of benefit to the potential adverse effects. ( 25687660 )
2015
27
A novel serum microRNA panel to discriminate benign from malignant ovarian disease. ( 25451316 )
2015
28
Impaired insulin signaling pathway in ovarian follicles of cows with cystic ovarian disease. ( 25813700 )
2015
29
Women with clomiphene citrate resistant polycystic ovarian disease: predictors of spontaneous ovulation after laparoscopic ovarian drilling. ( 24576485 )
2014
30
Ovarian dysfunction, obesity and pituitary tumors in female mice following neonatal exposure to low-dose diethylstilbestrol. ( 25450423 )
2014
31
Role of activin, inhibin, and follistatin in the pathogenesis of bovine cystic ovarian disease. ( 25001504 )
2014
32
Polycystic ovarian disease: still an enigma! ( 24685855 )
2014
33
Can treatment for polycystic ovarian disease induce ovarian tumour? A case report. ( 24596770 )
2014
34
Epidemiological description of cystic ovarian disease in argentine dairy herds: risk factors and effects on the reproductive performance of lactating cows. ( 25292292 )
2014
35
Altered expression of transforming growth factor-beta isoforms in bovine cystic ovarian disease. ( 25112788 )
2014
36
GC-MS analysis of Cocus nucifera flower extract and its effects on heterogeneous symptoms of polycystic ovarian disease in female Wistar rats. ( 25263979 )
2014
37
Assisted reproduction in polycystic ovarian disease: A multicentric trial in India. ( 23869152 )
2013
38
Adrenal ganglioneuroma in a patient with polycystic ovarian disease (PCOD): a rare association. ( 24145507 )
2013
39
Cutting edge: Ly49C/Ia8> neonatal NK cells predispose newborns to autoimmune ovarian disease induced by maternal autoantibody. ( 23960238 )
2013
40
Ovarian localization of 11I^-hydroxysteroid dehydrogenase (11I^HSD): effects of ACTH stimulation and its relationship with bovine cystic ovarian disease. ( 23972491 )
2013
41
Interaction between IGF1 and IGFBPs in bovine cystic ovarian disease. ( 23693122 )
2013
42
Changes in the expression of Heat Shock Proteins in ovaries from bovines with cystic ovarian disease induced by ACTH. ( 23937990 )
2013
43
Study of FMR1 gene association with ovarian dysfunction in a sample from the Basque Country. ( 23537988 )
2013
44
Steroid receptor mRNA expression in the ovarian follicles of cows with cystic ovarian disease. ( 21536311 )
2012
45
A molecular mechanism underlying ovarian dysfunction of polycystic ovary syndrome: hyperandrogenism induces epigenetic alterations in the granulosa cells. ( 22349439 )
2012
46
Tolerogenic DNA vaccine for prevention of autoimmune ovarian disease. ( 22221010 )
2012
47
Hirsutism, virilism, polycystic ovarian disease, and the steroid-gonadotropin-feedback system: a career retrospective. ( 22028409 )
2012
48
Environmentally induced epigenetic transgenerational inheritance of ovarian disease. ( 22570695 )
2012
49
Doppler imaging in the diagnosis of ovarian disease. ( 23480621 )
2012
50
Effect of shatapushpa taila matra basti and pathadi kwatha on poly cystic ovarian disease. ( 23559797 )
2012

Variations for Ovarian Disease

Expression for Ovarian Disease

Search GEO for disease gene expression data for Ovarian Disease.

Pathways for Ovarian Disease

GO Terms for Ovarian Disease

Cellular components related to Ovarian Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.61 AMH BMP15 GDF9 GNRH1 IGF1 IGFBP1
2 extracellular region GO:0005576 9.44 AMH BMP15 CGA GDF9 GNRH1 IGF1
3 endosome lumen GO:0031904 9.16 INS PRL

Biological processes related to Ovarian Disease according to GeneCards Suite gene sharing:

(show all 21)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of cell proliferation GO:0008284 9.96 CGA GDF9 IGF1 INS PRL
2 cell-cell signaling GO:0007267 9.9 AMH CGA GNRH1 INS
3 cellular protein metabolic process GO:0044267 9.77 BMP15 IGF1 IGFBP1 INS PRL
4 BMP signaling pathway GO:0030509 9.74 AMH BMP15 GDF9
5 positive regulation of phosphatidylinositol 3-kinase signaling GO:0014068 9.71 FSHR IGF1 INS
6 response to nutrient levels GO:0031667 9.7 IGF1 INS PRL
7 regulation of MAPK cascade GO:0043408 9.69 BMP15 FSHR GDF9
8 binding of sperm to zona pellucida GO:0007339 9.63 ZP1 ZP3 ZP4
9 positive regulation of glycolytic process GO:0045821 9.59 IGF1 INS
10 positive regulation of insulin receptor signaling pathway GO:0046628 9.58 IGF1 INS
11 positive regulation of glycogen biosynthetic process GO:0045725 9.58 IGF1 INS
12 female gonad development GO:0008585 9.58 CYP19A1 FOXL2 FSHR
13 single fertilization GO:0007338 9.56 FOXL2 ZP1 ZP3 ZP4
14 positive regulation of acrosome reaction GO:2000344 9.55 ZP3 ZP4
15 female gamete generation GO:0007292 9.5 BMP15 FSHR GDF9
16 positive regulation of humoral immune response GO:0002922 9.49 ZP3 ZP4
17 negative regulation of binding of sperm to zona pellucida GO:2000360 9.48 ZP3 ZP4
18 oocyte growth GO:0001555 9.43 FOXL2 GDF9
19 uterus development GO:0060065 9.33 CYP19A1 FOXL2 FSHR
20 regulation of signaling receptor activity GO:0010469 9.28 AMH BMP15 CGA GDF9 GNRH1 IGF1
21 gonad development GO:0008406 9.13 AMH CGA FSHR

Molecular functions related to Ovarian Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 growth factor activity GO:0008083 9.62 AMH BMP15 GDF9 IGF1
2 insulin-like growth factor receptor binding GO:0005159 9.37 IGF1 INS
3 receptor activator activity GO:0030546 9.26 IGF1 INS
4 acrosin binding GO:0032190 9.16 ZP3 ZP4
5 transforming growth factor beta receptor binding GO:0005160 9.13 AMH BMP15 GDF9
6 hormone activity GO:0005179 9.1 AMH CGA GNRH1 IGF1 INS PRL

Sources for Ovarian Disease

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....